Selank acetate (TP-7)
Not an FDA-approved drug. FDA states that compounded Selank may pose immunogenicity risks for certain routes and that important human safety information is lacking.
Current sourceSelank
What limited anxiety and imaging studies show—and what they cannot establish
Selank is a synthetic heptapeptide related to the tuftsin sequence and promoted online for anxiety and cognition. It is not an FDA-approved drug. The accessible human evidence is small, largely Russian-language, and concentrated in a limited research network; it does not establish product-wide safety, cognitive enhancement, or equivalence to approved anxiety treatments.
Editorial status
This page aggregates regulatory documents and published human research. Its claims, citations, populations, and limitations received an independent editorial evidence check. Last editorial audit: .
It has not been medically reviewed by a clinician. It provides general education, not diagnosis, treatment, dosing instructions, or advice for an individual. Use the product-specific official information and consult a qualified clinician or pharmacist for personal decisions.
Product and regulatory distinctions
A compound name is not one interchangeable set of instructions. Product, formulation, indication, labeling, and jurisdiction matter.
Products marketed as Selank
Marketing or regional availability does not establish FDA approval, consistent formulation, or U.S.-reviewed safety and effectiveness.
Current sourceClaim-by-claim evidence map
Each finding is tied to the population and product actually studied. Trial results are not personal predictions.
One small comparative study evaluated Selank and medazepam in people with anxiety-related diagnoses.
- Population
- 62 patients with generalized anxiety disorder or neurasthenia; 30 received Selank and 32 received medazepam.
- Finding
- The authors reported similar reductions on anxiety measures and additional antiasthenic effects with Selank.
- Limits
- The small, Russian-language study used an active comparator without a placebo arm; the abstract does not establish blinding, and replication by independent international groups is lacking.
A related clinical report described cytokine changes during Selank exposure.
- Population
- Patients with generalized anxiety disorder and neurasthenia receiving Selank for 14 days, plus laboratory experiments using peripheral blood cells.
- Finding
- Investigators reported changes in Th1/Th2 cytokine balance and IL-6-related laboratory measures.
- Limits
- These immune biomarkers are surrogate findings and do not establish prevention or treatment of infection, immune disease, anxiety, or another clinical outcome.
Selank produced acute resting-state connectivity differences in healthy volunteers.
- Population
- 52 healthy participants who received Selank, Semax, or placebo in an fMRI experiment.
- Finding
- Investigators reported treatment-related functional-connectivity differences involving the right amygdala and temporal cortex.
- Limits
- The study assessed short-term brain imaging, not anxiety remission, cognitive performance, everyday functioning, or long-term safety.
What this evidence does not answer
- No large, placebo-controlled, independently replicated trial defines Selank's efficacy or safety for generalized anxiety disorder.
- There is no adequate evidence that acute imaging or cytokine changes translate into cognitive enhancement, immune protection, or durable clinical benefit.
- Long-term safety, interactions, immunogenicity, and comparability among products sold as Selank remain poorly characterized.
Useful information to organize between visits
- Exact product name, chemical form, manufacturer, and lot
- Quality documentation addressing identity, purity, aggregation, sterility, and endotoxin as applicable
- The specific claim being evaluated and whether it is supported by a clinical outcome or only a biomarker
- Mood, sleep, cognition, and physical symptoms with timing and concurrent substances
- Questions for a licensed mental-health clinician or pharmacist
Questions to bring to a clinician or pharmacist
- 1.How strong is the evidence compared with established treatments for my concern?
- 2.Could an unapproved peptide complicate diagnosis or interact with current treatment?
- 3.What warning signs would require prompt evaluation?
- 4.How should an adverse event or suspected product-quality problem be reported?
Primary sources
- Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety RisksU.S. Food and Drug Administration · Published 2026 · Accessed July 12, 2026
- Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription DrugsU.S. Food and Drug Administration · Published 2020 · Accessed July 12, 2026
- Efficacy and possible mechanisms of action of Selank in generalized anxiety disorders and neurastheniaZhurnal Nevrologii i Psikhiatrii via PubMed · Published 2008 · Accessed July 12, 2026
- Immunomodulatory effects of Selank in patients with anxiety-asthenic disordersZhurnal Nevrologii i Psikhiatrii via PubMed · Published 2008 · Accessed July 12, 2026
- Functional Connectomic Approach to Studying Selank and Semax EffectsBulletin of Experimental Biology and Medicine via PubMed · Published 2020 · Accessed July 12, 2026
Turn scattered notes into a useful treatment history
Dosi organizes timing, locations, symptoms, reminders, and questions for your next appointment. It does not prescribe or replace your care team.
Start tracking free